浙江海正药业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2026年第一次临时股东会 证券代码：600267 证券简称：海正药业 公告编号：临2025-79号 召开的日期时间：2026 年 1 月 5 日 14 点 00 分 召开地点：浙江海正药业股份有限公司会议室（台州椒江区外沙路 46 号） (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 1 月 5 日 至2026 年 1 月 5 日 股东会召开日期：2026年1月5日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二)股东会召集人：董事会，经第十届董事会第十一次会议召开。 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 ...

证券代码：600267 证券简称：海正药业 公告编号：临 2025-76 号 浙江海正药业股份有限公司 第十届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）第十届董事会第十一次会 议于 2025 年 12 月 17 日以通讯方式召开，应参加本次会议董事 9 人，亲自参加 会议董事 9 人。本次会议的召开程序符合《公司法》和《公司章程》的规定，会 议合法有效。本次会议由公司董事长肖卫红先生主持，经审议，与会董事以通讯 表决方式通过了如下决议： 一、关于签署转让全资子公司浙江省医药工业有限公司 100%股权相关合同 的议案； 同意 9 票，反对 0 票，弃权 0 票。 本议案尚需提交公司 2026 年第一次临时股东会审议。 详见《浙江海正药业股份有限公司关于公开转让全资子公司浙江省医药工业 有限公司 100%股权的进展公告》，已登载于 2025 年 12 月 18 日的《中国证券报》 《上海证券报》《证券时报》和上海证券交易所网站（www.sse.com.c ...

海正药业公告，公司已与广州医药签订了股权交易合同及补充协议，转让价格为5亿元。此次交易为公 开挂牌转让，挂牌底价为4.3亿元，广州医药成功摘牌。交易尚需提交公司股东会审议，并需中国反垄 断审查机构经营者集中审查。交易完成后，省医药公司将不再纳入公司合并报表合并范围。 ...

Core Insights - The collaboration between Jiuzhoutong and Haizheng Pharmaceutical aims to reshape the retail channel competition in the pharmaceutical industry through a strategic partnership focused on complementary strengths in "industry + channel" [1][2] Group 1: Strategic Partnership - Jiuzhoutong's subsidiary, All-Qing Health, has signed a strategic cooperation agreement with Haizheng Pharmaceutical, becoming the exclusive agent responsible for the retail promotion of several core products, with an initial cooperation value exceeding 400 million yuan [1][2] - The partnership is expected to enhance both companies' performance and reflects a deeper transformation in the professional division of labor within the pharmaceutical industry [1][3] Group 2: Business Performance - Jiuzhoutong has been implementing its "Three New and Two Transformations" strategy since 2025, optimizing its business structure and improving operational efficiency, resulting in steady growth across its main business segments [1][4] - In the first three quarters of 2025, Jiuzhoutong achieved revenue of 119.33 billion yuan, a year-on-year increase of 5.20%, and a net profit of 1.975 billion yuan, up 16.46% [4][5] Group 3: Product Strategy - The new product strategy is a key component of Jiuzhoutong's growth, focusing on integrating resources to form a new product business organization matrix centered around CSO, which includes All-Qing Health and other subsidiaries [4][5] - Jiuzhoutong's CSO business generated sales revenue of 14.728 billion yuan in the first three quarters, with a significant contribution from core products like Kewai and Miko Bao, which saw a 15.26% increase in sales [5][6] Group 4: Market Expansion - The collaboration is expected to inject new vitality into the domestic pharmaceutical retail market, with plans for deep cooperation in global expansion, all-channel operations, and capital linkage [3][4] - The initial product offerings include key medications with strong market demand, and the retail sales scale is projected to double by 2026 [3][4]

Group 1 - Guangzhou Pharmaceutical Co., Ltd. announced a 500 million yuan acquisition of Zhejiang Pharmaceutical, which ranks 32nd in the national pharmaceutical industry with a revenue of 4.777 billion yuan [3] - The acquisition of Zhejiang Pharmaceutical is part of a broader trend of cross-provincial mergers in the pharmaceutical distribution sector, aimed at expanding market presence beyond local regions [3][4] - The pharmaceutical distribution industry is facing significant competition from larger players, with the top five companies generating over 100 billion yuan in annual revenue, prompting smaller firms to pursue mergers for scale and market reach [4][6] Group 2 - Guangzhou Pharmaceutical has previously invested 749 million yuan to acquire an 11.04% stake in Nanjing Pharmaceutical, becoming its second-largest shareholder [5] - The company is actively pursuing a strategy to transform and expand its operations, focusing on innovative drugs and high-end medical devices, while also enhancing digital transformation efforts [5] - The 2024 Pharmaceutical Distribution Industry Report indicates a trend towards increased market concentration, with a forecast for higher chain rates in the future [6]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its wholly-owned subsidiary, Haizheng Hangzhou, received the Certificate of Suitability (CEP) for the active pharmaceutical ingredient Everolimus from the European Directorate for the Quality of Medicines (EDQM) [1] Group 1 - The receipt of the CEP certificate indicates that the Everolimus active pharmaceutical ingredient meets the quality standards set by the European regulatory authority [1] - This certification may enhance the company's marketability and competitiveness in the European pharmaceutical market [1] - The approval is expected to facilitate the company's expansion and strengthen its position in the global pharmaceutical industry [1]

证券代码：600267 证券简称：海正药业 公告编号：临 2025-75 号 浙江海正药业股份有限公司 关于全资子公司依维莫司原料药获得 CEP 证书的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）全资子公司海正药 业杭州有限公司（简称"海正杭州公司"）收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称"EDQM"）签发 的 依 维莫 司 原 料 药欧 洲 药 典 适用 性 认 证证 书 （ Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP 证书"），现就相关情 况公告如下： 一、CEP证书相关信息 国际原料药业务易受海外市场环境变化、汇率波动等因素影响，敬请广大投 资者理性投资，注意投资风险。 特此公告。 产品剂型：原料药 证书编号：No. CEP 2024-3 ...

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for the active pharmaceutical ingredient Everolimus, indicating compliance with European Pharmacopoeia standards [1]. Group 1 - Haizheng Pharmaceutical's subsidiary, Haizheng Pharmaceutical Hangzhou Co., Ltd., is the entity that received the CEP certificate [1]. - The CEP certification is crucial for the marketing and distribution of Everolimus in Europe, enhancing the company's competitive position in the pharmaceutical market [1]. Group 2 - Everolimus is primarily indicated for adult patients with advanced renal cell carcinoma who have failed prior treatment with Sunitinib or Sorafenib [2]. - The drug is also applicable for adults with unresectable, locally advanced, or metastatic well-differentiated neuroendocrine tumors of the pancreas, gastrointestinal tract, or lung [2]. - Additionally, Everolimus is used in the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in both adults and children, as well as for the prevention of organ transplant rejection [2].

产品剂型：原料药 证书编号：No. CEP 2024-314 - Rev 00 证券代码：600267 证券简称：海正药业 公告编号：临 2025-75 号 浙江海正药业股份有限公司 关于全资子公司依维莫司原料药获得 CEP 证书的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）全资子公司海正药 业杭州有限公司（简称"海正杭州公司"）收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称"EDQM"）签发 的 依 维莫 司 原 料 药欧 洲 药 典 适用 性 认 证证 书 （ Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP 证书"），现就相关情 况公告如下： 一、CEP证书相关信息 药品名称：EVEROLIMUS/依维莫司 生产地址：浙江省杭州市富阳区胥口镇海正路1号 ...